ProjectFLYSYN-101
Basic data
Title:
FLYSYN-101
Duration:
01/02/2017 to 31/07/2019
Abstract / short description:
Phase Ib/IIa study to evaluate the safety, tolerability and preliminary efficacy of the Fc-optimized FLT3 antibody FLYSYN for the treatment of acute myeloid leukemia patients with minimal residual disease
Involved staff
Managers
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Other Faculty of Medicine facilities
Faculty of Medicine
University of Tübingen
University of Tübingen
Funders
Tübingen, Baden-Württemberg, Germany